AbbVie Inc. (ABBV)

NYQ – Real vaqt narxi. Valyuta: USD

207.86

+5.08 (2.51%)

Yopilishda: May 12, 2026, 4:01 PM EDT

206.20

-1.76 (-0.85%)

Bozor oldidan: May 13, 2026, 5:33 AM EDT

12.05.2026

AbbVie's Growth Engine Is Firing On All Cylinders

AbbVie is a compelling 'Buy' as it has strong momentum in existing drugs and has a robust pipeline. Robust Q1 2026 results: net revenue up 12.4% YoY, driven by Immunology (Skyrizi +29%, Rinvoq +20%) and Neuroscience (+24%). Management raised 2026 EPS guidance to $14.18, signaling 42% YoY growth and confidence in ABBV's diversified growth drivers and pipeline.

12.05.2026

AbbVie Deserves A Higher Multiple

AbbVie remains a buy as fundamentals strengthen and valuation sits near multiyear lows after recent stock underperformance. Q1 net revenues grew 12.4% YoY, indicating robust overall business activity despite some Immunology portfolio shakiness. Raised full-year 2026 EPS guidance signals management confidence, with underlying EPS growth projected at 14% annually after adjusting for IPR&D and milestone impacts.

11.05.2026

A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?

AbbVie's Skyrizi is one of its most important growth drivers. This drug could face competition from a newer medicine under development that appears more effective.

11.05.2026

AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing

AbbVie (ABBV) delivered strong Q1 2026 results, with $15B revenue (+12.4% YoY) and Skyrizi sales up 30.9%, prompting raised EPS guidance. Despite analyst concerns over new oral competitors like Icotyde, Skyrizi maintains a clear efficacy advantage and expanding indications, supporting robust growth. ABBV is trading at 14.2x 2026 EPS with a 0.84x PEG, offering compelling value amid 17% projected earnings growth and a $250/share price target.

09.05.2026

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AbbVie NYSE: ABBV told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

06.05.2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026.

Videolar

01.05.2026

Negative

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

13.01.2026

Positive

AbbVie reaches 3-year deal with White House to lower drug prices

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
ABBV	Citigroup	Neutral	undefined >> $205	May 14th 2025
ABBV	Cantor Fitzgerald	Overweight	undefined >> $210	April 22nd 2025
ABBV	Daiwa Securities	Neutral	undefined >> $180	December 5th 2024
ABBV	Leerink Partners	Outperform	undefined >> $206	November 22nd 2024
ABBV	Wolfe Research	Outperform	undefined >> $205	November 15th 2024
ABBV	Argus	Buy	undefined >> undefined	November 4th 2024
ABBV	Bernstein	Market Perform	undefined >> $203	October 17th 2024
ABBV	HSBC Securities	Buy	undefined >> $185	June 5th 2024

Press-relizlar

05.05.2026

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago.

AbbVie Inc. (ABBV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbbVie Inc. (ABBV)